Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
MORRISTOWN, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Oppenheimer 26th Annual Healthcare Conference as follows:
| Date: | Tuesday, December 8, 2015 | ||||
| Time: | 2:10 p.m. EST | ||||
| Location: | The Westin New York Grand Central, NYC | ||||
The presentation will be webcast and available on the Investors section of the Company’s website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Lisa Wilson, 212-452-2793 In-Site Communications [email protected] Media Relations Marianne Lambertson, (800) 793-2145 ext. 1012 Vice President, Strategic Development [email protected]
